ProteomAKI
Research type
Research Study
Full title
Identification of protein biomarkers and their association with mortality in patients with advanced cirrhosis with and without acute kidney injury. A pilot study.
IRAS ID
309593
Contact name
Juan Acevedo Haro
Contact email
Sponsor organisation
University Hospital Plymouth NHS Trust
Duration of Study in the UK
0 years, 9 months, 0 days
Research summary
This study consists on analysing the level of proteins present in the blood in patients with advanced liver cirrhosis with and without renal dysfunction. There is a need to identify new markers of diagnosis of renal dysfunction because the currently employed marker is suboptimal in patients with advanced cirrhosis. Therefore, there will be two groups: the first group with renal dysfunction included 8 patients who were recruited previously and consented to have their leftover samples for future studies. The second group is the control group, without renal dysfunction, who will be recruited (8 patients again to match Group 1). Patients will be consented when the patients are admitted into hospital for a planned intervention call paracentesis, which consists on draining most of the large amount of fluid these patients accumulate in their tummy. Because this procedure is elective the participants will be contacted in advanced and will have at least 2 days to read the participant information sheet. Once the consent is signed, a small amount of blood (2.7 mL) will be collected along with their standard blood tests. Their demographic data and the results of standard blood tests will be recorded. The participants will be discharged the same day as per usual practice. Their medical records will be accessed for 3 months after inclusion and relevant clinical events will be recorded as well. The samples will be analysed in the Proteomics laboratory of Plymouth University and it is expected that the level of some proteins would be different between the two groups. This pilot study will give essential information to develop a large multicentre trial to assess the clinical usefulness of the candidate proteins identified.
REC name
London - Surrey Borders Research Ethics Committee
REC reference
21/PR/1627
Date of REC Opinion
7 Mar 2022
REC opinion
Further Information Favourable Opinion